Phase 2 Cardiomyopathy Trial, Recruiting NCT06816251 Sponsor: Shandong Suncadia Medicine Co., Ltd. Condition: Cardiomyopathy
Back to Cardiomyopathy

Phase 2 Cardiomyopathy Trial, Recruiting

NCT06816251
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 85 years old (inclusive), either male or female
  • Your body mass index (a measure of body weight relative to height) is below 35 kg/m²
  • You understand what the study involves, are willing to take part, and can sign a consent form
  • If you are a woman who could become pregnant, you must have a negative pregnancy test before starting and must not be breastfeeding during the study
  • If you are a woman who could become pregnant, or a man whose partner could become pregnant, you must agree to use contraception and not donate eggs or sperm from the time of signing the consent form until 3 months after your last dose of the trial drug

Who may not be able to join:

  • You have a known or suspected condition (inherited, infiltrative, or storage-related) that causes the heart muscle to thicken (confirm with trial site)
  • You have episodes of irregular heart rhythms (atrial flutter or atrial fibrillation) with symptoms that were picked up at your screening appointment
  • You have fainted or had a serious fast heart rhythm problem (sustained ventricular tachycardia) in the 6 months before screening
  • You have taken part in another clinical trial for a drug or medical device within the 3 months before screening
  • The trial doctor believes, for any other reason, that the trial is not appropriate for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 18921102884

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shandong Suncadia Medicine Co., Ltd.
Registry
ClinicalTrials.gov
Start date
25 February 2025
Est. completion
1 August 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Adverse events (AEs); The incidence of left ventricular ejection fraction (LVEF) < 50%

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov